Viral protein R(Vpr) plays an important role in the replication and pathogenesis of Human immunodeficiency virus type 1(HIV-1). Some of the various functions attributed to Vpr, including the induction of G2/M cell cyc...Viral protein R(Vpr) plays an important role in the replication and pathogenesis of Human immunodeficiency virus type 1(HIV-1). Some of the various functions attributed to Vpr, including the induction of G2/M cell cycle arrest, activating the NF-κB pathway, and promoting viral reverse transcription, might be interrelated. To test this hypothesis, a panel of Vpr mutants were investigated for their ability to induce G2/M arrest and to activate the NF-κB pathway. The results showed that the Vpr mutants that failed to activate NF-κB also lost the activity to induce G2/M arrest, which suggests that inducing G2/M arrest via Vpr depends at least partially on the activation of NF-κB. This latter possibility is supported by data showing that knocking down the key factors in the NF-κB pathway – p65, Rel B, IKKα, or IKKβ– partially rescued the G2/M arrest induced by Vpr.Our results suggest that the NF-κB pathway is probably involved in Vpr-induced G2/M cell cycle arrest.展开更多
The human myxovirus resistance 2(Mx2/Mx B)protein,a member of interferon(IFN)-inducible dynamin-like large GTPases,restricts a number of virus infections.Inhibition of these viruses occurs at poorly-defined steps afte...The human myxovirus resistance 2(Mx2/Mx B)protein,a member of interferon(IFN)-inducible dynamin-like large GTPases,restricts a number of virus infections.Inhibition of these viruses occurs at poorly-defined steps after viral entry and has a common requirement for Mx B oligomerization.However,the GTPase activity is essential for the anti-viral effects of Mx B against herpesviruses and HBV but not HIV-1.To understand the role of Mx B GTPase activity,including GTP binding and GTP hydrolysis,in restriction of HIV-1 infection,we genetically separated these two functions and evaluated their contributions to restriction.We found that both the GTP binding and hydrolysis function of Mx B involved in the restriction of HIV-1 replication.The GTPase activity of Mx B contributed to its nuclear location,interaction with nucleoporins(NUPs)and HIV-1 capsids.Furthermore,Mx B disrupted the association between NUPs and HIV-1 cores dependently upon its GTPase activity.The function of GTPase activity was therefore multi-faceted,led to fundamentally distinct mechanisms employed by wild-type Mx B and GTPase activity defective Mx B mutations to restrict HIV-1 replication.展开更多
Despite the success of antiretroviral therapy(ART),efforts to develop new classes of antiviral agents have been hampered by the emergence of drug resistance.Dibenzo-indole-bearing aristolactams are compounds that have...Despite the success of antiretroviral therapy(ART),efforts to develop new classes of antiviral agents have been hampered by the emergence of drug resistance.Dibenzo-indole-bearing aristolactams are compounds that have been isolated from various plants species and which show several clinically relevant effects,including anti-inflammatory,antiplatelet,and antimycobacterial actions.However,the effect of these compounds on human immunodeficiency virus type 1(HIV-1)infection has not yet been studied.In this study,we discovered an aristolactam derivative bearing dibenzo[cd,f]indol-4(5 H)-one that had a potent anti-HIV-1 effect.A structure-activity relationship(SAR)study using nine synthetic derivatives of aristolactam identified the differing effects of residue substitutions on the inhibition of HIV-1 infection and cell viability.Among the compounds tested,1,2,8,9-tetramethoxy-5-(2-(piperidin-1-yl)ethyl)-dibenzo[cd,f]indol-4(5 H)-one(Compound 2)exhibited the most potent activity by inhibiting HIV-1 infection with a half-maximal inhibitory concentration(IC50)of 1.03 lmol/L and a half-maximal cytotoxic concentration(CC50)of 16.91 lmol/L(selectivity index,16.45).The inhibitory effect of the compounds on HIV-1 infection was linked to inhibition of the viral replication cycle.Mode-of-action studies showed that the aristolactam derivatives did not affect reverse transcription or integration;instead,they specifically inhibited Tat-mediated viral transcription.Taken together,these findings show that several aristolactam derivatives impaired HIV-1 infection by inhibiting the activity of Tat-mediated viral transcription,and suggest that these derivatives could be antiviral drug candidates.展开更多
Both thymocytes and tumor cells express M2 type isoenzyme of pyruvate kinase(M2PK),which is different from R type isoenzyme of pyruvate kinase(RPK)that is expressed in erythrocytes.In this report,the effect of RPK and...Both thymocytes and tumor cells express M2 type isoenzyme of pyruvate kinase(M2PK),which is different from R type isoenzyme of pyruvate kinase(RPK)that is expressed in erythrocytes.In this report,the effect of RPK and M2PK on the transcription of human immunodeficiency virus type 1(HIV-1)was tested.The results indicated that M2PK could enhance HIV-1 transcription from its long terminal repeat(LTR)promoter,while RPK did not have such an effect.Specific down-regulation of M2PK could inhibit HIV-1 transcription from its LTR region.Furthermore,it was found that the C terminal region of M2PK is responsible for this effect.Collectively,the cellular factor M2PK that is expressed in thymocytes could facilitate the transcription of HIV-1.展开更多
Raising a heterologous tier 2 neutralizing antibody(nAb)response remains a daunting task for HIV vaccine development.In this study,we explored the utility of diverse HIV-1 envelope(Env)immunogens in a sequential immun...Raising a heterologous tier 2 neutralizing antibody(nAb)response remains a daunting task for HIV vaccine development.In this study,we explored the utility of diverse HIV-1 envelope(Env)immunogens in a sequential immunization scheme as a solution to this task.This exploration stemmed from the rationale that gp145,a membrane-bound truncation form of HIV Env,may facilitate the focusing of induced antibody response on neutralizing epitopes when sequentially combined with the soluble gp140 form as immunogens in a prime-boost mode.We first showed that gp140 DNA prime-gp145 Tiantan vaccinia(TV)boost likely represents a general format for inducing potent nAb response in mice.However,when examined in rhesus macaque,this modality showed little effectiveness.To improve the efficacy,we extended the original modality by adding a strong protein boost,namely native-like SOSIP.664 trimer displayed on ferritin-based nanoparticle(NP),which was generated by a newly developed click approach.The resulting three-immunization regimen succeeded in eliciting tier-2 nAb response with substantial breadth when implemented in rhesus macaque over a short 8-week schedule.Importantly,the elicited nAb response was able to effectively contain viremia upon a heterologous SHIV challenge.Collectively,our studies highlighted that diversification of Env immunogens,in both types and formulations,under the framework of a sequential immunization scheme might open new opportunity toward HIV vaccine development.展开更多
Suitable animal models for human immunodeficiency virus type 1(HIV-1)infection are important for elucidating viral pathogenesis and evaluating antiviral strategies in vivo.The B-NSG(NOD-PrkdcscidIl2rgtm1/Bcge)mice tha...Suitable animal models for human immunodeficiency virus type 1(HIV-1)infection are important for elucidating viral pathogenesis and evaluating antiviral strategies in vivo.The B-NSG(NOD-PrkdcscidIl2rgtm1/Bcge)mice that have severe immune defect phenotype are examined for the suitability of such a model in this study.Human peripheral blood mononuclear cells(PBMCs)were engrafted into B-NSG mice via mouse tail vein injection,and the repopulated human T-lymphocytes were observed at as early as 3-weeks post-transplantation in mouse peripheral blood and several tissues.The humanized mice could be infected by HIV-1,and the infection recapitulated features of T-lymphocyte dynamic observed in HIV-1 infected humans,meanwhile the administration of combination antiretroviral therapy(cART)suppressed viral replication and restored T lymphocyte abnormalities.The establishment of HIV-1 infected humanized B-NSG mice not only provides a model to study virus and T cell interplays,but also can be a useful tool to evaluate antiviral strategies.展开更多
目的了解高效抗逆转录病毒治疗(highly active antiretroviral therapy,HAART)后HIV/AIDS患者T淋巴细胞免疫活化及CD4+CD45RA+T细胞的亚群变化,探讨抗病毒治疗对HIV感染者免疫恢复的影响。方法前瞻性分析105例接受HARRT治疗的HIV/AIDS患...目的了解高效抗逆转录病毒治疗(highly active antiretroviral therapy,HAART)后HIV/AIDS患者T淋巴细胞免疫活化及CD4+CD45RA+T细胞的亚群变化,探讨抗病毒治疗对HIV感染者免疫恢复的影响。方法前瞻性分析105例接受HARRT治疗的HIV/AIDS患者,流式细胞仪检测治疗前和治疗后1、3、6及12个月T淋巴细胞活化水平(CD38、HLA-DR的表达)及CD4+CD45RA+T淋巴细胞;同时选取未暴露且HIV-1抗体检测阴性者35名作为健康对照。结果HAART治疗前HIV/AIDS患者T淋巴细胞活化水平显著高于健康对照(P<0.01),HAART治疗后随治疗时间延长活化水平明显下降,治疗1个月时CD4+CD38+HLA-DR+及CD8+CD38+、CD8+HLA-DR+T淋巴细胞首先出现降低,治疗6个月时包含CD8+CD38+HLA-DR+T在内的4项活化指标均明显下降,差异有统计学意义(P<0.01);治疗12个月与6个月相比,CD8+CD38+HLA-DR+T表达水平继续降低(P<0.01),而其余3项活化指标差异无统计学意义。但HAART治疗12个月后,4项活化指标仍全部高于健康对照组(P<0.01)。CD4+CD45RA+T淋巴细胞百分比在治疗前及治疗后12个月均明显低于健康对照组。结论HIV/AIDS患者在HAART治疗后6个月免疫活化水平降低,但HAART并不能使免疫活化逆转;HAART治疗也不能恢复HIV感染后降低的CD4+CD45RA+T淋巴细胞的水平。展开更多
To investigate the prevalence of drug-resistance mutations,resistance to antiretroviral drugs,and the subsequent virological response to therapy in treatment-naive and antiretroviral-treated patients infected with HIV...To investigate the prevalence of drug-resistance mutations,resistance to antiretroviral drugs,and the subsequent virological response to therapy in treatment-naive and antiretroviral-treated patients infected with HIV/AIDS in Henan,China,a total of 431 plasma samples were collected in Queshan county between 2003 and 2004,from patients undergoing the antiretroviral regimen Zidovudine + Didanosine + Nevirapine(Azt+Ddi+Nvp).Personal information was collected by face to face interview.Viral load and genotypic drug resistance were tested.Drug resistance mutation data were obtained by analyzing patient-derived sequences through the HIVdb Program(http://hivdb.stanford.edu).Overall,38.5% of treatment-naive patients had undetectable plasma viral load(VL),the rate significantly increased to 61.9% in 0 to 6 months treatment patients(mean 3 months)(P<0.005)but again significantly decrease to 38.6% in 6 to 12 months treatment patients(mean 9 months)(P<0.001)and 40.0% in patients receiving more than 12 months treatment(mean 16 months)(P<0.005).The prevalence of drug resistance in patients who had a detectable VL and available sequences were 7.0%,48.6%,70.8%,72.3% in treatment-na?ve,0 to 6 months treatment,6 to 12 months treatment,and treatment for greater than 12 months patients,respectively.No mutation associated with resistance to Protease inhibitor(PI)was detected in this study.Nucleoside RT inhibitor(NRTI)mutations always emerged after non-nucleoside RT inhibitor(NNRTI)mutations,and were only found in patients treated for more than 6 months,with a frequency less than 5%,with the exception of mutation T215Y(12.8%,6/47)which occurred in patients treated for more than 12 months.NNRTI mutations emerged quickly after therapy begun,and increased significantly in patients treated for more than 6 months(P<0.005),and the most frequent mutations were K103N,V106A,Y181C,G190A.There had been optimal viral suppression in patients undergoing treatment for less than 6 months in Queshan,Henan.The drug resistance strains were highly prevale展开更多
基金supported by grants from the Chinese Ministry of Health (2012ZX10001006)the National Natural Science Foundation of China (81271812 and 31370182)+1 种基金111 Project (B08011)the Postgraduate Scholarship Program of the China Scholarship Council
文摘Viral protein R(Vpr) plays an important role in the replication and pathogenesis of Human immunodeficiency virus type 1(HIV-1). Some of the various functions attributed to Vpr, including the induction of G2/M cell cycle arrest, activating the NF-κB pathway, and promoting viral reverse transcription, might be interrelated. To test this hypothesis, a panel of Vpr mutants were investigated for their ability to induce G2/M arrest and to activate the NF-κB pathway. The results showed that the Vpr mutants that failed to activate NF-κB also lost the activity to induce G2/M arrest, which suggests that inducing G2/M arrest via Vpr depends at least partially on the activation of NF-κB. This latter possibility is supported by data showing that knocking down the key factors in the NF-κB pathway – p65, Rel B, IKKα, or IKKβ– partially rescued the G2/M arrest induced by Vpr.Our results suggest that the NF-κB pathway is probably involved in Vpr-induced G2/M cell cycle arrest.
基金supported by the National Science Foundation of China(81271818 and 81471940 to YF,and 81471941,81871659 and 81828005 to WH)
文摘The human myxovirus resistance 2(Mx2/Mx B)protein,a member of interferon(IFN)-inducible dynamin-like large GTPases,restricts a number of virus infections.Inhibition of these viruses occurs at poorly-defined steps after viral entry and has a common requirement for Mx B oligomerization.However,the GTPase activity is essential for the anti-viral effects of Mx B against herpesviruses and HBV but not HIV-1.To understand the role of Mx B GTPase activity,including GTP binding and GTP hydrolysis,in restriction of HIV-1 infection,we genetically separated these two functions and evaluated their contributions to restriction.We found that both the GTP binding and hydrolysis function of Mx B involved in the restriction of HIV-1 replication.The GTPase activity of Mx B contributed to its nuclear location,interaction with nucleoporins(NUPs)and HIV-1 capsids.Furthermore,Mx B disrupted the association between NUPs and HIV-1 cores dependently upon its GTPase activity.The function of GTPase activity was therefore multi-faceted,led to fundamentally distinct mechanisms employed by wild-type Mx B and GTPase activity defective Mx B mutations to restrict HIV-1 replication.
基金supported by grants from the Korea National Institute of Health (Grant Number:2019-NI-066-00 and 2020-ER5106-00)。
文摘Despite the success of antiretroviral therapy(ART),efforts to develop new classes of antiviral agents have been hampered by the emergence of drug resistance.Dibenzo-indole-bearing aristolactams are compounds that have been isolated from various plants species and which show several clinically relevant effects,including anti-inflammatory,antiplatelet,and antimycobacterial actions.However,the effect of these compounds on human immunodeficiency virus type 1(HIV-1)infection has not yet been studied.In this study,we discovered an aristolactam derivative bearing dibenzo[cd,f]indol-4(5 H)-one that had a potent anti-HIV-1 effect.A structure-activity relationship(SAR)study using nine synthetic derivatives of aristolactam identified the differing effects of residue substitutions on the inhibition of HIV-1 infection and cell viability.Among the compounds tested,1,2,8,9-tetramethoxy-5-(2-(piperidin-1-yl)ethyl)-dibenzo[cd,f]indol-4(5 H)-one(Compound 2)exhibited the most potent activity by inhibiting HIV-1 infection with a half-maximal inhibitory concentration(IC50)of 1.03 lmol/L and a half-maximal cytotoxic concentration(CC50)of 16.91 lmol/L(selectivity index,16.45).The inhibitory effect of the compounds on HIV-1 infection was linked to inhibition of the viral replication cycle.Mode-of-action studies showed that the aristolactam derivatives did not affect reverse transcription or integration;instead,they specifically inhibited Tat-mediated viral transcription.Taken together,these findings show that several aristolactam derivatives impaired HIV-1 infection by inhibiting the activity of Tat-mediated viral transcription,and suggest that these derivatives could be antiviral drug candidates.
基金This work was supported by the National Basic Research Program of China(973 Program)(No.2006CB504305)National Special Research Program of Major Infectious Diseases(No.2008ZX10001-002)the 111 Project(No.B06018).
文摘Both thymocytes and tumor cells express M2 type isoenzyme of pyruvate kinase(M2PK),which is different from R type isoenzyme of pyruvate kinase(RPK)that is expressed in erythrocytes.In this report,the effect of RPK and M2PK on the transcription of human immunodeficiency virus type 1(HIV-1)was tested.The results indicated that M2PK could enhance HIV-1 transcription from its long terminal repeat(LTR)promoter,while RPK did not have such an effect.Specific down-regulation of M2PK could inhibit HIV-1 transcription from its LTR region.Furthermore,it was found that the C terminal region of M2PK is responsible for this effect.Collectively,the cellular factor M2PK that is expressed in thymocytes could facilitate the transcription of HIV-1.
基金This work was supported by the National Natural Science Foundation of China(81672018,81561128008)the National Basic Research Program of China(973program#2014CB542502)+2 种基金the National 13th Five-Year Grand Program on Key Infectious Disease Control(2017ZX10202102)Shanghai Pujiang Program(19PJ1409100)Intramural Funding from Shanghai Public Health Clinical Center.
文摘Raising a heterologous tier 2 neutralizing antibody(nAb)response remains a daunting task for HIV vaccine development.In this study,we explored the utility of diverse HIV-1 envelope(Env)immunogens in a sequential immunization scheme as a solution to this task.This exploration stemmed from the rationale that gp145,a membrane-bound truncation form of HIV Env,may facilitate the focusing of induced antibody response on neutralizing epitopes when sequentially combined with the soluble gp140 form as immunogens in a prime-boost mode.We first showed that gp140 DNA prime-gp145 Tiantan vaccinia(TV)boost likely represents a general format for inducing potent nAb response in mice.However,when examined in rhesus macaque,this modality showed little effectiveness.To improve the efficacy,we extended the original modality by adding a strong protein boost,namely native-like SOSIP.664 trimer displayed on ferritin-based nanoparticle(NP),which was generated by a newly developed click approach.The resulting three-immunization regimen succeeded in eliciting tier-2 nAb response with substantial breadth when implemented in rhesus macaque over a short 8-week schedule.Importantly,the elicited nAb response was able to effectively contain viremia upon a heterologous SHIV challenge.Collectively,our studies highlighted that diversification of Env immunogens,in both types and formulations,under the framework of a sequential immunization scheme might open new opportunity toward HIV vaccine development.
基金supported by Grants to JHW from the National Grant Program on Key Infectious Disease(2018ZX10301101-003-002)the Natural Science Foundation of China(NSFC,81572001,81873965)+1 种基金the key project from Chinese Academy of Sciences(QYZDB-SSW-SMC059)WWS from NSFC(31800152)。
文摘Suitable animal models for human immunodeficiency virus type 1(HIV-1)infection are important for elucidating viral pathogenesis and evaluating antiviral strategies in vivo.The B-NSG(NOD-PrkdcscidIl2rgtm1/Bcge)mice that have severe immune defect phenotype are examined for the suitability of such a model in this study.Human peripheral blood mononuclear cells(PBMCs)were engrafted into B-NSG mice via mouse tail vein injection,and the repopulated human T-lymphocytes were observed at as early as 3-weeks post-transplantation in mouse peripheral blood and several tissues.The humanized mice could be infected by HIV-1,and the infection recapitulated features of T-lymphocyte dynamic observed in HIV-1 infected humans,meanwhile the administration of combination antiretroviral therapy(cART)suppressed viral replication and restored T lymphocyte abnormalities.The establishment of HIV-1 infected humanized B-NSG mice not only provides a model to study virus and T cell interplays,but also can be a useful tool to evaluate antiviral strategies.
文摘目的了解高效抗逆转录病毒治疗(highly active antiretroviral therapy,HAART)后HIV/AIDS患者T淋巴细胞免疫活化及CD4+CD45RA+T细胞的亚群变化,探讨抗病毒治疗对HIV感染者免疫恢复的影响。方法前瞻性分析105例接受HARRT治疗的HIV/AIDS患者,流式细胞仪检测治疗前和治疗后1、3、6及12个月T淋巴细胞活化水平(CD38、HLA-DR的表达)及CD4+CD45RA+T淋巴细胞;同时选取未暴露且HIV-1抗体检测阴性者35名作为健康对照。结果HAART治疗前HIV/AIDS患者T淋巴细胞活化水平显著高于健康对照(P<0.01),HAART治疗后随治疗时间延长活化水平明显下降,治疗1个月时CD4+CD38+HLA-DR+及CD8+CD38+、CD8+HLA-DR+T淋巴细胞首先出现降低,治疗6个月时包含CD8+CD38+HLA-DR+T在内的4项活化指标均明显下降,差异有统计学意义(P<0.01);治疗12个月与6个月相比,CD8+CD38+HLA-DR+T表达水平继续降低(P<0.01),而其余3项活化指标差异无统计学意义。但HAART治疗12个月后,4项活化指标仍全部高于健康对照组(P<0.01)。CD4+CD45RA+T淋巴细胞百分比在治疗前及治疗后12个月均明显低于健康对照组。结论HIV/AIDS患者在HAART治疗后6个月免疫活化水平降低,但HAART并不能使免疫活化逆转;HAART治疗也不能恢复HIV感染后降低的CD4+CD45RA+T淋巴细胞的水平。
基金Molecular epidemiology research of HIV-1 Drug resistance in China sponsored by the 973 program (2005CB523103) Molecular epidemiology research and new technologies in HIV surveillance in China sponsored by the 863 program (2006AA02Z418).
文摘To investigate the prevalence of drug-resistance mutations,resistance to antiretroviral drugs,and the subsequent virological response to therapy in treatment-naive and antiretroviral-treated patients infected with HIV/AIDS in Henan,China,a total of 431 plasma samples were collected in Queshan county between 2003 and 2004,from patients undergoing the antiretroviral regimen Zidovudine + Didanosine + Nevirapine(Azt+Ddi+Nvp).Personal information was collected by face to face interview.Viral load and genotypic drug resistance were tested.Drug resistance mutation data were obtained by analyzing patient-derived sequences through the HIVdb Program(http://hivdb.stanford.edu).Overall,38.5% of treatment-naive patients had undetectable plasma viral load(VL),the rate significantly increased to 61.9% in 0 to 6 months treatment patients(mean 3 months)(P<0.005)but again significantly decrease to 38.6% in 6 to 12 months treatment patients(mean 9 months)(P<0.001)and 40.0% in patients receiving more than 12 months treatment(mean 16 months)(P<0.005).The prevalence of drug resistance in patients who had a detectable VL and available sequences were 7.0%,48.6%,70.8%,72.3% in treatment-na?ve,0 to 6 months treatment,6 to 12 months treatment,and treatment for greater than 12 months patients,respectively.No mutation associated with resistance to Protease inhibitor(PI)was detected in this study.Nucleoside RT inhibitor(NRTI)mutations always emerged after non-nucleoside RT inhibitor(NNRTI)mutations,and were only found in patients treated for more than 6 months,with a frequency less than 5%,with the exception of mutation T215Y(12.8%,6/47)which occurred in patients treated for more than 12 months.NNRTI mutations emerged quickly after therapy begun,and increased significantly in patients treated for more than 6 months(P<0.005),and the most frequent mutations were K103N,V106A,Y181C,G190A.There had been optimal viral suppression in patients undergoing treatment for less than 6 months in Queshan,Henan.The drug resistance strains were highly prevale
